← Back to Search

Cisgender Women and Trans Individuals (CWTI) for Pre-Exposure Prophylaxis (S2P:CWTI Trial)

N/A
Waitlist Available
Led By Magdalena Sobieszczyk, MD, MPH
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

S2P:CWTI Trial Summary

This trial will evaluate attitudes and preferences about HIV prevention options over time, among people who are taking medication to prevent HIV, and among people who are not taking medication but are at risk of HIV.

Eligible Conditions
  • HIV Prevention
  • Pre-Exposure Prophylaxis

S2P:CWTI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Correlation Between PrEP modality preference and PrEP initiation/persistence in care
Percentage of participants on PrEP who remain engaged in sexual health care
PrEP Measurement Preferences Scale Score
Secondary outcome measures
Correlation of risk factors for low PrEP adherence and retention
Web-Based App User Satisfaction Score

S2P:CWTI Trial Design

1Treatment groups
Experimental Treatment
Group I: Cisgender Women and Trans Individuals (CWTI)Experimental Treatment1 Intervention
Cisgender women and trans individuals (CWTI) who are taking PrEP, have considered and decided not to take PrEP, or who have discontinued PrEP.

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,424 Previous Clinical Trials
2,472,852 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,862 Previous Clinical Trials
5,049,525 Total Patients Enrolled
Magdalena Sobieszczyk, MD, MPHPrincipal InvestigatorColumbia University
1 Previous Clinical Trials
1,000 Total Patients Enrolled

Media Library

Cisgender Women and Trans Individuals (CWTI) Clinical Trial Eligibility Overview. Trial Name: NCT05165745 — N/A
Pre-Exposure Prophylaxis Research Study Groups: Cisgender Women and Trans Individuals (CWTI)
Pre-Exposure Prophylaxis Clinical Trial 2023: Cisgender Women and Trans Individuals (CWTI) Highlights & Side Effects. Trial Name: NCT05165745 — N/A
Cisgender Women and Trans Individuals (CWTI) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05165745 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings for enrollment in this research initiative?

"Affirmative, the clinicaltrials.gov website states that this research is presently enrolling participants. The trial was initially publicized on October 25th 2021 and its most recent update occurred on December 8th 2021. There are 175 open spots at a single site for interested individuals to join the study."

Answered by AI

What is the maximum number of individuals permissible to partake in this research?

"Affirmative. The details on clinicaltrials.gov demonstrate that the study, which initially went live on October 25th 2021, is presently recruiting participants. This trial has a need for 175 individuals across just one medical centre."

Answered by AI
~51 spots leftby Mar 2025